Speak with one of our advisors: 0800 085 6663 or

New cancer detection early evidence backs opportunity for employers to support smokers

Results from the largest ever randomised trial for lung cancer have provided new evidence of the value of employer-led testing to save lives and reduce healthcare costs.

The initial results from a study by NHS Scotland ECLS of 10,000 high-risk smokers demonstrate a higher than expected cancer detection rate (sensitivity) of 81%, with a specificity (chance that a negative test excludes lung cancer) of 91%. The data is based on the EarlyCDT-Lung blood test developed by Nottingham firm OncImmune that detects autoantibody biomarkers. The research findings are to be officially released on September 7th 2015 at the International Association for the Study of Lung Cancer’s 16th World Conference on Lung Cancer.

The EarlyCDT-Lungblood test has been used by a number of UK employers since early 2013 through the Check4Cancer screening services.

Professor Gordon Wishart, Medical Director of Check4Cancer, said: “In May 2013, Check4Cancer ran an extremely successful “Love Your Lungs” lung cancer awareness and early detection programme for Hewlett Packard, with engagement of more than 2,500 employees in the UK and Ireland. We look forward to continuing to work closely with OncImmune to deliver the EarlyCDT-Lung test to our clients.”

To read the full article, please visit HR Review website.

© 2020 Check4Cancer, Lower Court 3-4, Copley Hill Business Park, Cambridge Road, Cambridge, CB22 3GN
Registered in England and Wales. Company registration number 08866941